Effects of Tapentadol on Pain, Motor Symptoms and Cognitive Functions in Parkinson's Disease

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2018 Oct 2

PMID 30271190

Citations 11

Authors

Ulderico Freo

Maurizio Furnari

Carlo Ori

Affiliations

Soon will be listed here.

Abstract

Background: Pain is a common and undertreated non-motor symptom in patients with Parkinson's disease (PD). Opioids have been seldom used in PD because they could worsen cognitive and motor functions.

Objective: We aimed to assess efficacy and tolerability of tapentadol in PD patients.

Methods: We retrospectively reviewed 21 PD patients treated with tapentadol extended release (ER) for chronic pain. Patients were evaluated before treatment and at 3 and 6 months during treatment for pain intensity (current, 24-hour average, and minimum and worst) with a 0-10 Numerical Rating Scale and the painDETECT questionnaire; for motor symptom severity with the Unified PD Rating Scale part III and the Hoehn and Yahr scale; for cognitive functions with Mini-Mental Status Examination, Corsi's Block-Tapping test, Digit Span test, Digit-Symbol Substitution test, FAS test, Rey's Auditory Verbal Learning test, Trail-Making test A and B and the 9-Hole Peg test; for anxiety and depression with the Hospital Anxiety and Depression Scale; and for the quality of life with the Short Form-12. Data were analyzed by 1-way analysis of variance and paired -test, and by Friedman's and Wilcoxon's tests. Statistical significance was taken in all cases as <0.05.

Results: Pain intensity decreased over the course of treatment. No differences were found in PD symptom severity and dopaminergic drug dosages between pretreatment and treatment evaluations. No decrement in cognitive neuropsychological performances was found and an improvement was observed in Digit Span test, Digit-Symbol Substitution test, and FAS test. The levels of anxiety, depression, and quality of life improved. Overall, tapentadol ER was well tolerated and most patients reported no or mild and short-lived gastroenterological and neurological side effects.

Conclusion: These results indicate the potential efficacy and tolerability of medium-high doses of tapentadol ER for the treatment of pain in PD.

Citing Articles

Long-Term Outcome and Predictors of Transversus Abdominis Plane Block for Chronic Post-Hernioplasty Pain.

Freo U, Furnari M J Clin Med. 2024; 13(14).

PMID: 39064080 PMC: 11278023. DOI: 10.3390/jcm13144039.

A Pragmatic Review on Spinal Cord Stimulation Therapy for Parkinson's Disease Gait Related Disorders: Gaps and Controversies.

Hvingelby V, Carra R, Terkelsen M, Hamani C, Capato T, Kosutzka Z Mov Disord Clin Pract. 2024; 11(8):927-947.

PMID: 38899557 PMC: 11329578. DOI: 10.1002/mdc3.14143.

Opioids in the Elderly Patients with Cognitive Impairment: A Narrative Review.

Rekatsina M, Paladini A, Viswanath O, Urits I, Myrcik D, Pergolizzi J Pain Ther. 2022; 11(2):381-394.

PMID: 35380373 PMC: 9098742. DOI: 10.1007/s40122-022-00376-y.

Paracetamol: A Review of Guideline Recommendations.

Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E J Clin Med. 2021; 10(15).

PMID: 34362203 PMC: 8347233. DOI: 10.3390/jcm10153420.

An overview of pain in Parkinson's disease.

Tai Y, Lin C Clin Park Relat Disord. 2021; 2:1-8.

PMID: 34316612 PMC: 8302194. DOI: 10.1016/j.prdoa.2019.11.004.

References

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Goetz C, Poewe W, Rascol O, Sampaio C, Stebbins G, Counsell C . Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004; 19(9):1020-8. DOI: 10.1002/mds.20213. View

Braak H, Sastre M, Bohl J, de Vos R, Del Tredici K . Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007; 113(4):421-9. DOI: 10.1007/s00401-007-0193-x. View

de la Fuente-Fernandez R, Stoessl A . The placebo effect in Parkinson's disease. Trends Neurosci. 2002; 25(6):302-6. DOI: 10.1016/s0166-2236(02)02181-1. View

Freynhagen R, Baron R, Gockel U, Tolle T . painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006; 22(10):1911-20. DOI: 10.1185/030079906X132488. View

Santos J, Alarcao J, Fareleira F, Vaz-Carneiro A, Costa J . Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; (5):CD009923. PMC: 7205027. DOI: 10.1002/14651858.CD009923.pub2. View

Karras B, McKee N, Regier L, Stone S . Opioids for chronic noncancer pain in the elderly: an osteoarthritis case. Can Fam Physician. 2011; 57(8):907-11. PMC: 3155447. View

Tzschentke T, Christoph T, Kogel B, Schiene K, Hennies H, Englberger W . (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1):265-76. DOI: 10.1124/jpet.107.126052. View

Panjabi S, Panjabi R, Shepherd M, Lawson K, Johnsrud M, Barner J . Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: effect on pain, depressive symptoms, and cognition. Pain Med. 2008; 9(8):985-93. DOI: 10.1111/j.1526-4637.2008.00483.x. View

10.

Madeo G, Schirinzi T, Natoli S, Pierantozzi M, Stefani A, Dauri M . Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. J Neurol. 2015; 262(9):2164-70. DOI: 10.1007/s00415-015-7823-3. View

11.

. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA. 1997; 278(2):125-30. DOI: 10.1001/jama.1997.03550020057038. View

12.

Berg D, Becker G, Reiners K . Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. J Neural Transm (Vienna). 2000; 106(7-8):725-8. DOI: 10.1007/s007020050192. View

13.

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

14.

Rickli A, Liakoni E, Hoener M, Liechti M . Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2017; 175(3):532-543. PMC: 5773950. DOI: 10.1111/bph.14105. View

15.

Kodraliu G, Mosconi P, Groth N, Carmosino G, Perilli A, Gianicolo E . Subjective health status assessment: evaluation of the Italian version of the SF-12 Health Survey. Results from the MiOS Project. J Epidemiol Biostat. 2001; 6(3):305-16. DOI: 10.1080/135952201317080715. View

16.

Baron R, Eberhart L, Kern K, Regner S, Rolke R, Simanski C . Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. Pain Pract. 2016; 17(5):678-700. DOI: 10.1111/papr.12515. View

17.

Giuffrida R, Vingerhoets F, Bogousslavsky J, Ghika J . [Pain in Parkinson's disease]. Rev Neurol (Paris). 2005; 161(4):407-18. DOI: 10.1016/s0035-3787(05)85070-2. View

18.

Cao L, Peng X, Huang Y, Wang B, Zhou F, Cheng R . Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016; 2016:6383240. PMC: 5056271. DOI: 10.1155/2016/6383240. View

19.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

20.

Schrag A, Horsfall L, Walters K, Noyce A, Petersen I . Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2014; 14(1):57-64. DOI: 10.1016/S1474-4422(14)70287-X. View